Synthesis and Evaluation of Heterocyclic Catechol Mimics as Inhibitors of Catechol-O-methyltransferase (COMT).
Harrison, S.T., Poslusney, M.S., Mulhearn, J.J., Zhao, Z., Kett, N.R., Schubert, J.W., Melamed, J.Y., Allison, T.J., Patel, S.B., Sanders, J.M., Sharma, S., Smith, R.F., Hall, D.L., Robinson, R.G., Sachs, N.A., Hutson, P.H., Wolkenberg, S.E., Barrow, J.C.(2015) ACS Med Chem Lett 6: 318-323
- PubMed: 25815153 
- DOI: https://doi.org/10.1021/ml500502d
- Primary Citation of Related Structures:  
4XUC, 4XUD, 4XUE - PubMed Abstract: 
3-Hydroxy-4-pyridinones and 5-hydroxy-4-pyrimidinones were identified as inhibitors of catechol-O-methyltransferase (COMT) in a high-throughput screen. These heterocyclic catechol mimics exhibit potent inhibition of the enzyme and an improved toxicity profile versus the marketed nitrocatechol inhibitors tolcapone and entacapone. Optimization of the series was aided by X-ray cocrystal structures of the novel inhibitors in complex with COMT and cofactors SAM and Mg(2+). The crystal structures suggest a mechanism of inhibition for these heterocyclic inhibitors distinct from previously disclosed COMT inhibitors.
Organizational Affiliation: 
Department of Medicinal Chemistry, Global Structural Biology, Chemical Modeling and Informatics, and Department of Neuroscience Research, Merck Research Laboratories , Sumneytown Pike, West Point, Pennsylvania 19486, United States.